SARS CoV 2 News and Research

RSS

The T cell responses in COVID-19 recovered individuals

A recent study demonstrates that functional CD4+ and CD8+ T cells specifically targeting the entire proteome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain active in individuals who have recovered from severe or mild coronavirus disease 2019 (COVID-19). Moreover, the magnitude of T cell response is correlated with the antibody response. The study is published in the journal Nature Immunology.

8 Sep 2020

Racial disparities could be the key reason for COVID-19 mortality among Black essential workers

Racial disparities among essential workers could be a key reason that Black Americans are more likely than whites to contract and die of COVID-19, according to researchers at the University of Utah.

8 Sep 2020

Study suggests a wider distribution range of Ebola virus carriers in Africa than previously assumed

Zaire ebolavirus is among the deadliest of all known Ebola viruses for humans and is most likely transmitted by various species of bats.

8 Sep 2020

High levels of blood clotting factor V in severe COVID‐19 associated with worse outcomes

Patients hospitalized with severe COVID-19 infections who have high levels of the blood clotting protein factor V are at elevated risk for serious injury from blood clots such as deep vein thrombosis or pulmonary embolism, investigators at Massachusetts General Hospital (MGH) have found.

8 Sep 2020

Study addresses the role of macrophage activation syndrome in COVID-19

Scientists review macrophage activation syndrome — a feature of the cytokine storm that kills patients with severe cases of COVID-19, as well as possible treatments.

8 Sep 2020

Research suggests school reopenings contribute to rise in COVID-19 cases

A study recently published on the preprint server medRxiv in September 2020 by researcher Richard Beesley at Juvenile Arthritis Research reports on the impact of school reopenings on the spread of the virus.

8 Sep 2020

Avacta to launch Affimer-based ELISA test for SARS-CoV-2 virus detection

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the coronavirus that causes COVID-19.

From Avacta Life Sciences Ltd. 8 Sep 2020

Limited gut inflammation in COVID-19

A new study by researchers at the Icahn School of Medicine at Mount Sinai and published on the preprint server medRxiv in September 2020 shows that gut infection with this virus produces primarily mucosal immunity but also a limited inflammatory response.

8 Sep 2020

Study finds strong T cell responses in patients recovered from COVID-19

Oxford University researchers have found that natural infection with COVID-19 produces a robust T cell response, including inducing T cell ‘memory’ to potentially fight future infections.

8 Sep 2020

Antibody-mediated platelet death linked to COVID-19 severity

A new study by University of Tuebingen researchers shows the strong association between platelet apoptosis and the thrombotic manifestations that may underlie critical COVID-19 illness.

7 Sep 2020

Scientists describe various dynamic structures of the SARS-CoV-2 spike protein

Early in the pandemic, scientists uncovered the role of the ACE2 receptor in SARS-CoV-2, the virus that causes the coronavirus disease (COVID-19). The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and the angiotensin-converting enzyme 2 (ACE2) receptors act as a lock and key for cell infection.

7 Sep 2020

PI3K/mTOR and topoisomerase inhibitors suggested as candidates to reduce expression of ACE2

A recent study published in the preprint server medRxiv in September 2020 shows that the already approved drug families called P13K/mTOR and topoisomerase inhibitors may be useful in reducing individual susceptibility to the virus.

7 Sep 2020

SARS-CoV-2 containment and elimination strategy will require long-term population-wide prevention measures

By introducing a model that reveals long SARS-CoV-2 transmission chains and inadequate passive surveillance systems, a new medRxiv* preprint paper shows that bringing the infection completely under control will have to rely on presumptive, stringent, longer and more burdensome population-wide prevention measures already employed against community transmission.

7 Sep 2020

Important research on SARS-CoV-2 proteins using proximity labeling

A team of Canadian scientists has recently discovered a wide-range interaction between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and host proteins using proximity-dependent biotinylation approaches.

7 Sep 2020

Pooled saliva testing increases COVID-19 testing capacity

Now, a new study by researchers at Yale School of Medicine and published on the preprint server medRxiv in September 2020 shows that pooled saliva samples can save resources and increase testing capacity, making a significant difference in the management of the pandemic.

7 Sep 2020

D-dimer - A sensitive novel biomarker of COVID-19 mortality

Now, a new study published on the preprint server medRxiv* reports the use of D-dimer in predicting the risk of mortality in COVID-19.

7 Sep 2020

Rehabilitation speeds coronavirus recovery

Now, a team of researchers at the University Clinic in Innsbruck in Austria has found that the long-term lung and heart damage in coronavirus disease (COVID-19) patients who recovered tend to improve over time.

7 Sep 2020

Using proteins to track SARS-CoV-2 infections through wastewater

A new study published on the preprint server medRxiv* in September 2020 describes the measurement of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins in wastewater as a reliable way to track the virus in the community.

6 Sep 2020

Novel RNA vaccine from Arcturus Therapeutics protects mice against SARS-CoV-2

A new study published on the preprint server bioRxiv in September 2020 reports a novel RNA vaccine platform that shows robust protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in mice and performs much better than a conventional mRNA vaccine. This could allow single-dose immunization, allowing progress towards global vaccination.

6 Sep 2020

Seasonal influenza and COVID-19 risk

In a new study published on the preprint server medRxiv, researchers from Laval University and McGill University in Canada reviewed evidence from 18 relevant studies on a possible interaction between influenza vaccines on non-influenza respiratory disease (NIRD).

6 Sep 2020